Salix rifaximin "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Final approval of Salix' traveler's diarrhea antibiotic rifaximin awaits results from a third study that began in early 2002, FDA says in Oct. 25 "approvable" letter. Salix hopes to have enrollment in the study wrapped up by the end of the year. The company is evaluating new brand names for the product following FDA's rejection of the proposed name Lumenax
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.